Cytotoxicity profiles of PR-171 and bortezomib
| Cell type . | Cell line . | Origin . | Cell viability IC50 (nmol/L) 1 h treatment/72 h washout . | . | Cell viability IC50 (nmol/L) 72 h treatment . | . | ||
|---|---|---|---|---|---|---|---|---|
| . | . | . | PR-171 . | Bortezomib . | PR-171 . | Bortezomib . | ||
| Hematologic tumor | RPMI 8226 | Multiple myeloma | 71 ± 22 | 303 ± 52 | 10 ± 3.3 | 4.5 ± 2.5 | ||
| HS-Sultan | B-cell lymphoma (Burkitt's) | 135 ± 30 | 454 ± 60 | 5.2 ± 2.3 | 5.4 ± 2.0 | |||
| Molt4 | Acute lymphoblastic leukemia | 31 ± 17 | 126 ± 52 | 3.1 ± 1.6 | 6.2 ± 2.7 | |||
| RL | B cell lymphoma (NHL) | 164 ± 92 | 814 ± 476 | 2.4 ± 0.4 | 3.4 ± 2.0 | |||
| Solid tumor | HT-29 | Colorectal adenocarcinoma | 350 ± 84 | 2,190 ± 390 | 6.2 ± 3.9 | 5.0 ± 2.6 | ||
| MiaPaCa-2 | Pancreatic carcinoma | 1,110 ± 240 | >6,500 | 8.9 ± 6.5 | 8.3 ± 2.3 | |||
| A549 | Lung carcinoma | 1,200 ± 900 | 4,600 ± 1,900 | 20 ± 8 | 13 ± 8 | |||
| Nontransformed | NHDF | Normal skin | 389 ± 128 | 2,460 ± 1,120 | 14 ± 4.5 | 6.3 ± 4.1 | ||
| HUVEC | Normal umbilical vein | 455 ± 45 | 3,510 ± 390 | 7.2 ± 1.3 | 3.5 ± 0.5 | |||
| Cell type . | Cell line . | Origin . | Cell viability IC50 (nmol/L) 1 h treatment/72 h washout . | . | Cell viability IC50 (nmol/L) 72 h treatment . | . | ||
|---|---|---|---|---|---|---|---|---|
| . | . | . | PR-171 . | Bortezomib . | PR-171 . | Bortezomib . | ||
| Hematologic tumor | RPMI 8226 | Multiple myeloma | 71 ± 22 | 303 ± 52 | 10 ± 3.3 | 4.5 ± 2.5 | ||
| HS-Sultan | B-cell lymphoma (Burkitt's) | 135 ± 30 | 454 ± 60 | 5.2 ± 2.3 | 5.4 ± 2.0 | |||
| Molt4 | Acute lymphoblastic leukemia | 31 ± 17 | 126 ± 52 | 3.1 ± 1.6 | 6.2 ± 2.7 | |||
| RL | B cell lymphoma (NHL) | 164 ± 92 | 814 ± 476 | 2.4 ± 0.4 | 3.4 ± 2.0 | |||
| Solid tumor | HT-29 | Colorectal adenocarcinoma | 350 ± 84 | 2,190 ± 390 | 6.2 ± 3.9 | 5.0 ± 2.6 | ||
| MiaPaCa-2 | Pancreatic carcinoma | 1,110 ± 240 | >6,500 | 8.9 ± 6.5 | 8.3 ± 2.3 | |||
| A549 | Lung carcinoma | 1,200 ± 900 | 4,600 ± 1,900 | 20 ± 8 | 13 ± 8 | |||
| Nontransformed | NHDF | Normal skin | 389 ± 128 | 2,460 ± 1,120 | 14 ± 4.5 | 6.3 ± 4.1 | ||
| HUVEC | Normal umbilical vein | 455 ± 45 | 3,510 ± 390 | 7.2 ± 1.3 | 3.5 ± 0.5 | |||
NOTE: Cell viability was measured with CellTiter-Glo reagent either after continuous compound exposure for 72 h or with 1 h compound exposure followed by a 72 h washout period. Values reported are the mean ± SD from ≥3 determinations.